Jefferies Financial Group Inc. decreased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 97.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,510 shares of the company's stock after selling 170,370 shares during the quarter. Jefferies Financial Group Inc.'s holdings in DaVita were worth $690,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the stock. United Capital Financial Advisors LLC raised its holdings in DaVita by 2.6% during the 4th quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock valued at $361,000 after acquiring an additional 62 shares during the period. Freedom Investment Management Inc. raised its holdings in DaVita by 3.6% during the 4th quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock valued at $268,000 after acquiring an additional 62 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in DaVita by 2.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock valued at $531,000 after acquiring an additional 69 shares during the period. UMB Bank n.a. raised its holdings in DaVita by 65.5% during the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after acquiring an additional 76 shares during the period. Finally, Exchange Traded Concepts LLC raised its holdings in DaVita by 8.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 970 shares of the company's stock valued at $148,000 after acquiring an additional 79 shares during the period. 90.12% of the stock is owned by institutional investors.
Insider Buying and Selling at DaVita
In other DaVita news, insider James O. Hearty sold 2,351 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the transaction, the insider owned 26,038 shares of the company's stock, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.00% of the company's stock.
DaVita Trading Up 1.5%
DVA stock traded up $1.86 during trading on Friday, reaching $129.55. The company had a trading volume of 949,567 shares, compared to its average volume of 872,829. DaVita Inc. has a 52 week low of $126.07 and a 52 week high of $179.60. The company has a market cap of $9.26 billion, a P/E ratio of 12.74, a PEG ratio of 0.88 and a beta of 1.09. The business has a 50 day moving average of $140.15 and a 200 day moving average of $147.07. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.20.
DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same quarter last year, the firm earned $2.00 earnings per share. The business's revenue for the quarter was up 6.1% on a year-over-year basis. As a group, sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on DVA. Truist Financial set a $148.00 price target on shares of DaVita in a report on Friday. Barclays cut their target price on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research report on Thursday. Finally, Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, DaVita presently has an average rating of "Hold" and a consensus price target of $166.75.
Check Out Our Latest Stock Report on DaVita
DaVita Company Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading

Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.